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Objectives. We sought to investigate the long-term efficacy of
slow-pathway catheter ablation in patients with spontaneous,
documented paroxysmal supraventricular tachycardia (PSVT)
and dual atrioventricular (AV) node pathways but without induc-
ible tachycardia.
Background. The lack of reproduction of clinical PSVT by
programmed electrical stimulation, which is not uncommon in AV
node reentrant tachycardia (AVNRT), is a dilemma in making the
decision of the therapeutic end point of radiofrequency catheter
ablation.
Methods. Twenty-seven patients (group A) with documented
but noninducible PSVT and with dual AV node pathways were
prospectively studied. Programmed electrical stimulation could
induce a single AV node echo beat in 12 patients, double echo
beats in 4 patients and none in 11 patients at baseline or during
isoproterenol infusion. Of the patients in group A, 16 underwent
slow-pathway catheter ablation and 11 did not. The clinical and
electrophysiologic characteristics of the 27 patients were com-
pared with those of patients with dual AV node pathways and
inducible AVNRT (group B, n 5 55) and patients with dual AV
node pathways alone without clinical PSVT (group C, n 5 47).
Results. During 23 6 13 months of follow-up, none of the 16
patients with slow-pathway catheter ablation had recurrence of
PSVT. However, 7 of the 11 patients without ablation had PSVT
recurrence at 13 6 14 months of follow-up (p < 0.03 by Kaplan-
Meier analysis). Compared with groups B and C, group A
consisted predominantly of men who had better retrograde AV
node conduction and a narrower zone for anterograde slow-
pathway conduction.
Conclusions. Slow-pathway catheter ablation is highly effective
in eliminating spontaneous PSVT in which the tachycardia is not
inducible despite the presence of dual AV node pathways.
(J Am Coll Cardiol 1998;31:855–60)
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The inability to induce clinical paroxysmal supraventricular
tachycardia (PSVT) by programmed electrical stimulation
often precludes the correct diagnosis of the arrhythmia and
makes it difficult to judge the therapeutic end point of radio-
frequency catheter ablation. This dilemma is not infrequently
encountered in patients with atrioventricular (AV) node reen-
trant tachycardia (AVNRT) (1–3). The application of radio-
frequency catheter ablation to treat patients with spontaneous
but noninducible PSVT and with demonstrated dual AV node
pathways has not been well established (4). Furthermore, its
long-term therapeutic benefit is not clear.
In the present study, we intended to test the hypothesis that
slow-pathway catheter ablation by radiofrequency current is
beneficial for long-term elimination of PSVT recurrence in
patients with documented, spontaneous tachycardia with dem-
onstrated dual AV node pathways but without inducible
AVNRT.
Methods
Patient group. Between March 1990 and March 1997, we
prospectively studied 27 patients (group A) who had sponta-
neous, electrocardiographically documented PSVT with the
presence of dual AV node pathways but without inducible
tachycardia in the electrophysiology laboratory. Group A
represented 5.2% of the overall 520 patients receiving radio-
frequency catheter ablation for AVNRT at two institutions
(National Taiwan University Hospital and University of Mas-
sachusetts Medical Center). There were 19 men and 8 women
in group A (mean age 42 6 19 years, range 14 to 74). The
associated medical diagnosis was coronary artery disease in
two patients and hypertension in three patients. None had
accessory pathways, atrial flutter/fibrillation or ventricular
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tachycardia according to the patient’s history and electrophysi-
ologic study. The clinical PSVT had a mean rate of 184 6 28
beats/min (i.e., 333 6 53 ms in cycle length). The frequency of
PSVT attacks varied from once a month to twice a year, with
most patients having them less than four times a year, for a
duration of at least 1 year. All the clinical sustained PSVTs
could be terminated by either carotid sinus massage or intra-
venous verapamil or adenosine. The clinical characteristics of
these 27 patients are listed in Table 1.
To distinguish the underlying electrophysiologic mecha-
nism(s), two other groups of patients with dual AV node
pathways and different clinical manifestations were included
for comparative analysis. Group B consisted of 55 patients (18
men and 37 women; mean age 44 6 14 years, range 16 to 70)
randomly enrolled from the remaining 493 patients receiving
radiofrequency catheter ablation for AVNRT in the present
study. They all had clinically documented and electrically
inducible AVNRT. Group C consisted of 47 patients with dual
AV node pathways but without clinical or inducible AVNRT.
They were randomly enrolled from a total of 365 patients
receiving radiofrequency catheter ablation therapy for acces-
sory pathways (n 5 46) or atrial tachycardia (n 5 1). None of
the 47 patients in group C had any further clinical tachyar-
rhythmia in a follow-up period of 18 6 9 months (range 6 to
36).
Electrophysiologic study. After obtaining the informed,
written consent, the patients were studied in a postabsorptive
state. All antiarrhythmic drugs were discontinued for at least 5
half-lives. For the study, standard electrode catheters were
positioned at the high right atrium, the His bundle region, the
coronary sinus and the right ventricular apex for pacing and
recording. Programmed electrical stimulation was performed
from the high right atrium and the right ventricle at two driving
cycle lengths at minimum (usually 600 and 400 ms) and up to
double extrastimuli. If the tachycardia was not inducible,
isoproterenol infusion was administered to increase the heart
rate by at least 25%. The same stimulation protocol was
Abbreviations and Acronyms
AV 5 atrioventricular
AVNRT 5 atrioventricular node reentrant tachycardia
ECG 5 electrocardiogram
PSVT 5 paroxysmal supraventricular tachycardia
VA 5 ventriculoatrial
Table 1. Clinical and Electrophysiologic Characteristics in 27 Patients Who Had Spontaneous, Noninducible Tachycardia and Dual
Atrioventricular Node Pathways
Pt. No./
Gender
Age
(years)
SVT Rate
(beats/min)
Exercise-
Provocable AVN Duality
No. of
AVNREB SP-RFA
No. of RFA
Applications
Early
Success
F/U
(months) Recurrence Re-RFA
1/M 18 210 Yes Ant (1) 0 No — — 33 No No
2/M 32 185 No Ant (1) 0 No — — 4 Yes Yes
3/M 37 200 Yes Ant (1) 0 No — — 45 No No
4/F 55 160 No Ant (1) 0 No — — 1 Yes No
5/M 25 185 No Ant (1) 0 No — — 3 Yes Yes
6/M 74 170 No Ant (1) 0 No — — 18 No No
7/M 61 165 Yes Ant (1) 0 No — — 14 No No
8/F 51 170 Yes Ant (1) 1 No — — 8 Yes No
9/M 25 202 No Ant (1) 0 No — — 3 Yes Yes
10/M 56 150 No Ant (1) 0 No — — 16 Yes No
11/M 24 134 Yes Ant (1) 1 No — — 1 Yes Yes
12/M 26 180 Yes Ant (1) 1 Yes 6 Yes 35 No —
13/F 43 175 No Ant (1) 2 Yes 15 Yes 27 No —
14/M 22 205 Yes Ant, Retr (1) 2 Yes 12 Yes 31 No —
15/F 14 230 No Ant (1) 1 Yes 9 Yes 33 No —
16/M 28 190 Yes Ant (1) 2 Yes 20 Yes 21 No —
17/M 36 210 Yes Ant (1) 1 Yes 12 Yes 30 No —
18/F 21 240 Yes Ant (1) 1 Yes 8 Yes 19 No —
19/M 42 215 Yes Ant (1) 1 Yes 5 Yes 17 No —
20/F 35 210 Yes Ant, Retr (1) 2 Yes 7 Yes 10 No —
21/M 24 220 Yes Ant (1) 1 Yes 4 Yes 6 No —
22/F 69 145 No Ant (1) 1 Yes 1 Yes 6 No —
23/F 62 182 No Ant (1) 1 Yes 3 Yes 7 No —
24/M 55 185 Yes Ant (1) 1 Yes 3 Yes 36 No —
25/M 69 142 No Ant, Retr (1) 1 Yes 1 Yes 15 No —
26/M 44 177 No Ant (1) 0 Yes 1 Yes 54 No —
27/M 73 144 Yes Ant (1) 0 Yes 3 Yes 17 No —
Ant (1), Retr (1) 5 anterograde, retrograde AVN duality; AVN duality 5 dual AV node pathways; AVNREB 5 inducible AV node reentrant echo beats; F/U 5
follow-up after electrophysiologic study with or without intervention; F 5 female; M 5 male; Re-RFA 5 repeat radiofrequency catheter ablation; RFA 5
radiofrequency catheter ablation; SP-RFA 5 slow-pathway radiofrequency catheter ablation; SVT 5 documented clinical supraventricular tachycardia.
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repeated during isoproterenol infusion and during the washout
phase. If the tachycardia was still not inducible, intravenous
atropine (1.0 mg) and low right atrial pacing were used in some
patients. The stimulation amplitude was two times the diastolic
threshold with a pulse width of 2 ms delivered by a digitized
stimulator (Bloom Associates). A surface electrocardiogram
(ECG) (at least leads I, aVF and V1) and multiple intracardiac
tracings were simultaneously displayed and recorded by a
multichannel oscilloscope (EVR-110, PPG Biomedical or Car-
diolab, Prucker Engineering Inc.). Intracardiac local electro-
grams were filtered between 30 and 500 Hz and printed at a
paper speed of 100 or 200 mm/s.
The clinical tachycardia in the 27 patients in group A was
suspected to be AVNRT according to two criteria (5,6): 1) a
narrow QRS complex or QRS complex with rate-dependent
aberrancy, with no discernible P wave (Fig. 1A) or with a small
pseudo–S wave in the inferior leads and a pseudo–R9 wave in
Figure 1. Two examples of spontaneous PSVTs in patients with dual
AV node pathways and noninducible tachycardia. A, Narrow QRS
complex tachycardia (rate 202 beats/min) without a recognizable
P wave. B, Narrow QRS complex tachycardia (rate 165 beats/min) with
pseudo–S waves in the inferior leads and a pseudo–R9 wave in lead V1.
Both were considered in favor of the diagnosis of AVNRT.
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lead V1 (Fig. 1B); and 2) the presence of dual AV node
pathways. A single, rarely double, slow–fast AV node reentrant
echo beat by atrial stimulation or a fast–slow AV node
reentrant echo beat by ventricular stimulation was usually
inducible. The presence of dual AV node pathways (1,2) was
defined as prolongation of the AH interval during atrial pacing
or extrastimulus or the HA interval during ventricular pacing
or extrastimulus for .50 ms with a 10-ms decrease of the
coupling interval.
Radiofrequency catheter ablation. Radiofrequency cathe-
ter ablation of the slow pathway was attempted after discussion
with the patients about the result of electrophysiologic study
and the potential risk and benefit of the procedure. The
ablation target was guided by both the anatomy and the
characteristics of the local electrograms (7,8). During applica-
tion of radiofrequency current, the surface ECG and intracar-
diac electrograms were continuously monitored. In case of the
occurrence of junctional rhythm or tachycardia, atrial over-
drive pacing was introduced for assessing AV conduction. The
end point of catheter ablation was elimination of the slow-
pathway conduction, demonstrated by the disappearance of
dual AV node pathways and AV node echo beats. The
radiofrequency current was delivered as an unmodulated sine
wave of 500 Hz between the 4-mm distal electrode of the
ablation catheter (Webster-Cordis or Dr. Osypka GmbH,
Grenzach-Wyhlen, Germany) and a large, dispersive patch
electrode on the back. Either power-controlled or temperature-
monitored radiofrequency energy application was used for
cardiac lesion formation. The radiofrequency generators
(Radionics 3-C; HAT 200S, Dr. Osypka GmbH, Grenzach-
Wyhlen, Germany) are commercially available and equipped
with continuous display of power, voltage, current, impedance
and temperature.
Follow-up. After the electrophysiologic study with or with-
out concomitant radiofrequency catheter ablation, all 27 pa-
tients in group A were followed up monthly at the clinic. In
case of recurrent palpitations, ECG documentation by an
ambulatory event recorder (Heart Watch, Instromedix), 12-
lead ECG or 24-h Holter monitor was required for arrhythmia
confirmation. Electrophysiologic study and a possible repeat
catheter ablation was performed when indicated clinically.
Data analysis. The functional characteristics of the AV
node and the fast and slow pathways in these 27 patients
(group A) were analyzed before and after isoproterenol infu-
sion and were compared retrospectively with the other two
groups of patients (groups B and C). Continuous data are
expressed as the mean value 6 SD, compared by analysis of
variance and the multiple comparison test. Categoric data were
compared by the N3M chi-square test. Kaplan-Meier life-
table analysis (9) was applied to evaluate the actuarial PSVT-
free rate in the 27 group A patients with (n 5 16) or without
(n 5 11) slow-pathway catheter ablation. The difference be-
tween curves was analyzed by the log-rank test. For those
patients with recurrence of PSVT, the follow-up ended at the
time of recurrence. A p value , 0.05 was considered statisti-
cally significant.
Results
Clinical characteristics (Table 1). Nineteen of the 27
patients in group A were men, which was in contrast to the
dominance of women in group B (37 of 55 patients were
women, p 5 0.003 vs. group A) or the even distribution of men
and women in group C (p 5 0.09). Clinically, the PSVT was
exercise-provocable in 14 of the 27 patients in group A and in
20 of the 55 patients in group B (p 5 0.27). The frequency of
PSVT attacks was 4 6 3 (range 1 to 7) times a year for group
A patients and 10 6 11 (range 3 to 42) (p 5 0.007) times a year
for group B patients.
Electrophysiologic characteristics. The electrophysiologic
characteristics of the AV node and the fast and slow pathways
in group A patients at baseline and during isoproterenol
infusion are listed in Tables 2 and 3 and compared with the
other two groups of patients with dual AV node pathways.
Compared with the group B patients who had dual AV
node pathways and inducible AVNRT, group A patients were
characterized by a narrow slow-pathway anterograde conduc-
tion zone. The anterograde slow-pathway effective refractory
period was longer and the difference between the fast pathway
and the slow pathway effective refractory periods was smaller.
Also, the difference in the 1:1 AV conduction cycle length
between the fast pathway and the slow pathway was narrower
in group A patients at baseline and during isoproterenol
infusion (Table 2 and 3).
Compared with the group C patients who had dual AV
node pathways without clinical or inducible AVNRT, group A
patients had better retrograde ventriculoatrial (VA) conduc-
tion at baseline and during isoproterenol infusion (Table 2 and
3).
Programmed electrical stimulation in the 27 group A
patients induced a single AV node reentrant echo beat in 12
patients, double echo beats in 4 and none in 11. Slow-pathway
catheter ablation was accepted in 16 patients (14 with single or
double echo beats, 2 without an echo beat) and refused in 11
patients (2 with a single echo beat, 9 without an echo beat).
There were no immediate or late complications after radiofre-
quency catheter ablation.
Long-term effect of slow-pathway catheter ablation. Dur-
ing the follow-up period of at least 6 months (mean 23 6 13,
range 6 to 54), none of the 16 group A patients receiving the
slow-pathway catheter ablation had recurrence of clinical
tachycardia. In contrast, 7 of the remaining 11 group A
patients without slow-pathway ablation had recurrence of
PSVT during the mean follow-up period of 13 6 14 months
(range 1 to 45). Six of the 7 patients had the recurrence within
9 months (4 patients within 3 months). The benefit of slow-
pathway catheter ablation with regard to prevention of PSVT
recurrence is confirmed by the Kaplan-Meier life-table analysis
(p , 0.03, between patients with slow-pathway ablation and
those without it). Four patients with recurrent tachycardia
consequently received slow-pathway catheter ablation and
remained free of arrhythmia recurrence during subsequent
follow-up of 43 6 17 months (range 26 to 61). The other three
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patients who had recurrent tachycardia refused catheter abla-
tion and were treated with calcium channel blockers or beta-
blockers.
Discussion
The present study demonstrated that slow-pathway catheter
ablation was highly effective in the long-term elimination of
PSVT recurrence in patients with dual AV node pathways, who
had spontaneous but noninducible supraventricular tachycar-
dia. This specific group of patients consisted predominantly of
men who characteristically had a narrow slow-pathway antero-
grade conduction zone and relatively better retrograde VA
conduction, as compared with those with dual AV node
pathways plus inducible AVNRT or those with only dual AV
node pathways without clinical tachycardia.
Clinical features. The presence of dual AV node pathways
and spontaneous but noninducible tachycardia is an ambiguous
indication for radiofrequency catheter ablation (4). The long-
term benefit of catheter ablation in this group of patients is
uncertain. Recently, Bogun et al. (3) first reported the high
efficacy of slow-pathway catheter ablation in prevention of
PSVT recurrence in seven patients with spontaneous, docu-
mented but noninducible supraventricular tachycardia during a
follow-up period of 15 6 10 months. Our study, which has a
larger patient group (n 5 16) and a longer mean follow-up
Table 2. Comparison of Baseline Electrophysiologic Characteristics in Groups A, B and C
Group A
(n 5 27)
Group B
(n 5 55)
Group C
(n 5 47)
p Value
ANOVA
Group
A vs. B
Group
A vs. C
Group
B vs. C
Sinus CL 839.7 6 147.5 744.4 6 101.4 730.2 6 148.9 0.002 0.001 0.004 NS
AH 93.5 6 18.3 72.5 6 17.2 76.5 6 15.8 0.0001 , 0.0001 0.0002 NS
1:1 FPCL 394.1 6 93.0 419.3 6 83.5 390.4 6 82.0 NS — — —
1:1 SPCL 353.3 6 44.6 355.8 6 60.1 338.7 6 55.6 NS — — —
DCL 24.8 6 11.7 84.2 6 70.7 54.7 6 48.7 0.0005 0.0006 0.008 0.02
FP ERP 379.3 6 93.7 330.6 6 71.6 329.4 6 69.9 0.013 0.01 0.01 NS
SP ERP 329.3 6 65.0 245.0 6 36.5 252.1 6 55.8 0.0001 , 0.0001 , 0.0001 NS
DERP 55.8 6 35.9 91.0 6 60.5 77.2 6 50.3 0.023 0.008 NS NS
(AH) max 344.7 6 122.4 361.3 6 90.2 289.4 6 64.9 0.001 NS 0.042 , 0.0001
AVBCL 364.1 6 97.1 351.1 6 60.0 345.5 6 65.3 NS — — —
VABCL 374.6 6 66.3 360.0 6 78.4 453.5 6 103.6 0.0002 NS 0.003 , 0.0001
1:1 SPC* 21 38 30 NS — — —
1:1 VAC* 24 55 29 , 0.0001 NS 0.03 , 0.0001
*Categoric data were analyzed by the N3M chi-square test. All data, except 1:1 SPC and 1:1 VAC, are expressed as the mean value 6 SD, in milliseconds; 1:1
SPC and 1:1 VAC are expressed as the number of patients. Continuous data were analyzed by analysis of variance (ANOVA) and the multiple comparison test. AH 5
atrio-Hisian interval; (AH) max 5 maximal achievable AH interval; AVBCL 5 atrioventricular conduction basic cycle length; CL 5 cycle length; 1:1 FPCL and 1:1
SPCL 5 minimal 1:1 conduction cycle lengths of the fast pathway and the slow pathway, respectively; FP ERP and SP ERP 5 effective refractory periods of the fast
pathway and the slow pathway, respectively; DCL 5 difference in the minimal 1:1 conduction cycle lengths between the fast pathway and slow pathway; DERP 5
difference in the effective refractory periods between the fast pathway and slow pathway; 1:1 SPC 5 1:1 anterograde slow-pathway conduction; VABCL 5
ventriculoatrial blocking cycle length; 1:1 VAC 5 1.1 ventriculoatrial conduction.
Table 3. Comparison of Electrophysiologic Characteristics in Groups A, B and C During Isoproterenol Infusion
Group A
(n 5 27)
Group B
(n 5 23)
Group C
(n 5 47)
p Value
ANOVA
Group
A vs. B
Group
A vs. C
Group
B vs. C
1:1 FPCL 305.2 6 40.5 310.4 6 56.5 329.2 6 59.5 NS — — —
1:1 SPCL 279.4 6 20.7 281.3 6 32.0 292.3 6 38.8 NS — — —
DCL 22.8 6 8.3 44.4 6 35.8 48.1 6 42.6 0.049 0.02 0.02 NS
FP ERP 298.5 6 41.2 277.0 6 50.3 284.3 6 53.6 NS — — —
SP ERP 266.5 6 41.9 222.0 6 28.4 225.8 6 45.5 0.0002 0.0004 0.0007 NS
DERP 35.8 6 17.0 65.5 6 43.1 63.5 6 34.4 0.0016 0.003 0.0005 NS
(AH) max 226.3 6 67.4 305.9 6 93.7 250.0 6 61.6 0.008 0.02 NS 0.004
AVBCL 279.6 6 42.1 270.0 6 34.2 292.6 6 45.0 NS — — —
VABCL 305.2 6 65.4 268.7 6 26.7 361.1 6 80.5 0.0004 0.02 0.005 , 0.0001
1:1 SPC 18 16 26 NS — — —
1:1 VAC 27 23 35 , 0.01 NS 0.04 NS
All data, except 1:1 SPC and 1:1 VAC, are expressed as the mean value 6 SD, in milliseconds; 1:1 SPC and 1:1 VAC are expressed as the number of patients.
Abbreviations and statistics as in Table 2.
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period (23 6 13 months, range 6 to 54) largely confirms their
observations. Furthermore, our patients are predominantly
men and the tachycardias are often exercise provocable, in
contrast to the features of patients with inducible AVNRT
(7,8,10,11). Electrophysiologically, this group of patients has
excellent anterograde and retrograde AV node conduction but
a narrower anterograde slow-pathway conduction zone, which
may disturb the initiation of sustained AVNRT by pro-
grammed electrical stimulation.
Noninducibility of AVNRT. The initiation of sustained,
common AVNRT requires a critical interaction between the
anterograde slow pathway and the retrograde fast pathway
(1,2,12,13). The former determines the spontaneous rate of
AVNRT, whereas the latter limits the fastest rate of AVNRT.
A poor retrograde fast-pathway conduction generally predicts
the low probability of initiating AVNRT (14). The present
study compares the electrophysiologic characteristics between
the three groups of patients with dual AV node pathways but
variable AVNRT inducibility or spontaneous initiation, and
suggests that the electrophysiologic mechanism for the nonin-
ducibility of AVNRT is most likely the result of a narrow
slow-pathway anterograde conduction zone. The narrow gap in
anterograde refractoriness between the fast pathway and the
slow pathway, together with the longer anterograde slow-
pathway effective refractory period, reduces the chance of
sustaining slow-pathway conduction and inducing AVNRT,
despite the functional integrity of retrograde fast-pathway
conduction in this specific group of patients. The simple
addition of isoproterenol (15) or atropine (16), which mainly
improves retrograde fast pathway conduction, is unlikely to
recondition the slow-pathway anterograde conduction zone for
initiation of AVNRT. Whether the functional heterogeneity of
the AV junction in patients with dual AV node pathways is the
result of anatomic variation or autonomic nervous imbalance
remains unknown (17–19).
Study limitations. First, intravenous atropine and pacing
from other atrial sites were not routinely added to the stimu-
lation protocol to facilitate AVNRT induction. However, our
study used up to double atrial and ventricular extrastimuli at
two or more driving cycle lengths before, during and after
infusion of isoproterenol. Whether further perturbation of
sympathovagal balance would help the induction is uncertain.
Second, the majority of the group A patients with inducible
single or double echo beats underwent slow-pathway catheter
ablation, but few of those without echo beats had the proce-
dure. The effect of the slightly uneven inclusion of the patients
on the long-term benefit of the slow-pathway catheter ablation
cannot be assessed.
Conclusions. Our study showed that slow-pathway catheter
ablation appears beneficial in the elimination of PSVT recur-
rence in patients who have spontaneous, noninducible tachy-
cardia and who have dual AV node pathways.
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